Edition:
Deutschland

Agilent Technologies Inc (A.N)

A.N on New York Stock Exchange

71.97USD
16 Feb 2018
Change (% chg)

$-0.05 (-0.07%)
Prev Close
$72.02
Open
$71.88
Day's High
$72.68
Day's Low
$71.65
Volume
719,368
Avg. Vol
539,383
52-wk High
$75.00
52-wk Low
$50.56

A.N

Chart for A.N

About

Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics... (more)

Buy/Sell

Sell Hold Buy
1.67 Mean rating from 15 analysts

Overall

Beta: 1.28
Market Cap(Mil.): $21,356.51
Shares Outstanding(Mil.): 321.83
Dividend: 0.13
Yield (%): 0.80

BRIEF-Agilent Technologies CEO Michael Mcmullen's 2017 Total Compensation Was $10.1 Mln Vs $8.9 Mln In 2016

* AGILENT TECHNOLOGIES INC - CEO MICHAEL R. MCMULLEN'S 2017 TOTAL COMPENSATION WAS $10.1 MILLION VERSUS $8.9 MILLION IN 2016 - SEC FILING‍​ Source text (http://bit.ly/2BRfYYG) Further company coverage:

BRIEF-Agilent Technologies Board Increases Size From 11 To 12 Members

* AGILENT TECHNOLOGIES INC SAYS ON JANUARY 17, BOARD INCREASED ITS SIZE FROM 11 TO 12 MEMBERS -SEC FILING Source text: (http://bit.ly/2EVj4Zh) Further company coverage:

BRIEF-Agilent Expands Cell Analysis Portfolio With Acquisition Of Luxcel Biosciences

* AGILENT EXPANDS CELL ANALYSIS PORTFOLIO WITH ACQUISITION OF LUXCEL BIOSCIENCES

BRIEF-Agilent Technologies Q4 non-gaap earnings per share $0.67

* Agilent Technologies reports fourth-quarter fiscal year 2017 financial results

BRIEF-Agilent technologies increases cash dividend to 14.9 cents per share

* Agilent technologies increases cash dividend to 14.9 cents per share Source text for Eikon: Further company coverage:

EXCLUSIVE-Siemens mandates three banks for IPO of Healthineers unit -sources

* Stock market float expected in June/July 2018 -sources (Adds valuation, details)

BRIEF-Agilent Technologies receives expanded FDA approval for Dako PD-L1 IHC 22C3 pharmDx

* Agilent Technologies receives expanded FDA approval for the use of Dako PD-L1 IHC 22C3 pharmDx companion diagnostic in gastric or gastroesophageal junction (GEJ) cancer Source text for Eikon: Further company coverage:

BRIEF-Agilent Technologies announces sponsorship deal with LabCentral

* Announced platinum sponsorship agreement with LabCentral, co to equip LabCentral's shared laboratory workspace with co's technology​

BRIEF-Agilent announces expanded use of cancer diagnostic in U.S.

* Says ‍FDA approved cancer diagnostic for use in cases of UC and of Squamous Cell Carcinoma of head & neck​ Source text for Eikon: Further company coverage:

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.24%
Rohstoffe -0.32%
Industrie -0.21%
Konjunktur abhängige Waren & Dienstleistungen -0.18%
Konjunktur unabhängige Waren & Dienstleistungen -0.16%
Finanzindustrie -0.08%
Pharma -0.07%
Technologie -0.20%
Telekommunikation -0.05%